Better Health. Better Life.

M Pharmaceutical Inc. Appoints Kim Whittemore of San Diego, California to Its Board of Directors

VANCOUVER, B.C., CANADA (March 3rd, 2017) - M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FWB: T3F2), (the "Company" or “M Pharma”) announces that Kim Whittemore has been appointed to the Company’s Board of Directors.

“Kim Whittemore provides M Pharma with extensive knowledge and expertise within the women’s health space, a central focus of our business growth strategy,” said Gary Thompson, M Pharma’s President and CEO. 

Kim Whittemore is a passionate advocate for women’s health and sexual health. She has vast experience in the fields of digital health, wearable tech and women’s health and through her management consulting practice, works with clients on business strategy and digital marketing. (Partial client list at kimwhit.com).  Ms. Whittemore is a University of Pennsylvania International Relations graduate, completed MIT executive courses in Computer Science and has an advanced certificate in digital marketing.  In her early career,  Ms. Whittemore held senior executive positions with DecisionOne Corporation, Verizon and AT & T after beginning her career at the National Security Agency (NSA).

“As a C-Suite management consultant, Kim has developed and implemented go-to-market strategies in the healthcare space, and specifically within the women’s health space, including the launch of a digital health service for infertility treatments. Her experience and negotiating skills, noting that she has secured an eight figure licensing agreement with market leading companies, will be of great benefit to M Pharma,” said Mr. Thompson. “Kim’s experience and passion provide a great asset to our company and we are excited to have her join our team.” 

“As new members continue to join our Board, I would like to thank Mr. George Tsafalas for his tremendous leadership and guidance in serving M Pharma since its inception. George is resigning from the Board to make way for Kim, but will continue to support the Company as a senior business consultant,” said Gary Thompson.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management.  In addition to C-103, a reformulation of orlistat, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights.  The Company acquired an FDA cleared fertility product branded as ToConceive that represents its first offering in the women's health field and has recently acquired a suite of products, the foundation of which is based on a patented and FDA cleared topical gel combining menthol & L-arginine.  This innovative formulation can be paired with many different ingredients to address a multitude of medical issues, including a female dysfunction application that been submitted for patent protection.

M Pharma trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”

For more information contact:
Investor Relations
Phone: +1 604 428 0511          
info@m-pharma.ca
www.m-pharma.ca

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval, commercialization of the rights to the Company’s biomedical & drug technologies, and acquisition of new products.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca.  Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: C-103 and Trimeo are investigational drugs or devices and are not currently available outside of approved clinical trials.  Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.  

Drug Treatment Portfolio

Obesity, Weight Management Treatment

C-103 is a novel reformulation of orlistat, patented until 2030 in the U.S.  Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter).  Proven safe and effective in over 100 clinical trials, orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007.  The C-103 reformulation addresses adverse events reported by over 90% of orlistat users. These adverse events have led to the decline in Orlistat sales to approximately $200 million in recent years. 

C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable adverse events. Unlike other weight loss drugs:

  • Orlistat is not an amphetamine
  • Orlistat does not affect the central nervous system
  • Orlistat is not systemically absorbed
  • Orlistat is the only FDA-approved OTC weight loss drug because of its safety
  • Orlistat is the only FDA-approved weight loss drug for adolescent patients (age 12-18)

Infertility Treatment

ToConceive is an innovative new infertility treatment that offers hope and assistance to the millions of couples worldwide struggling to start a family. Our product is an easy to use topical gel that helps to balance the pH of the vagina and is clinically proven to increases a women’s natural production of transudate (sexual lubrication). This increase in natural transudate is required for successful “Sperm Capacitation” to occur. Without the process of Sperm Capacitation, the sperm would not have the ability to travel the required distance to the ovum or have the appropriate chemical makeup for successful conception to occur.

ToConceive is a women’s health treatment supported by a FDA 510K clearance and is protected by four USPTO patents. ToConceive’s proven ability to increase a woman’s natural production of transudate results in significantly higher success rates for couples trying to conceive, without the added expense, or stress, associated with assisted reproduction treatments.